This presentation and the accompanying oral presentation contain data and information obtained from third-party studies and internal company analysis of such data and information. BeOne has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is subject to the same qualifications noted above. This presentation is intended for the investor community only; it is not intended to promote the products referenced herein or otherwi ...

Company Strategy & R&D Model - BeOne aims to transform cancer care globally by delivering innovative medicines faster, more equitably, and affordably[12, 16] - The company's R&D model leverages a prolific research organization, global manufacturing, efficient clinical development, and global commercial access to achieve superior R&D returns[25] - BeOne focuses on delivering high-quality innovation by designing superior molecules with exceptional profiles and halting programs that don't meet high standards; over 60 preclinical programs have been terminated in the past 3.5 years[30, 32] - The company is building a deep pipeline, aiming to deliver 8-10 highly differentiated new molecular entities (NMEs) into the clinic in each focused disease area in the next 3-6 years[42] Hematology Portfolio & CLL - BeOne is positioned to address unmet needs in CLL with a wholly-owned portfolio including BRUKINSA, sonrotoclax, and BTK CDAC[93] - BRUKINSA is the only BTKi to demonstrate PFS superiority over ibrutinib in a head-to-head Phase 3 R/R CLL trial[100] - In treatment-naive CLL/SLL patients, 60-month PFS with zanubrutinib was 72.2% in patients with del(17p), similar to 75.8% in patients without del(17p)[105] - Sonrotoclax + zanubrutinib achieved fast and deep responses in TN CLL/SLL, with 84% uMRD at week 48 in the 160mg dose group and 92% uMRD in the 320mg dose group[133] Solid Tumor Portfolio - The global CDK4/6i market is large and growing, estimated at approximately $13 billion[244] - BG-C9074 (B7-H4 ADC) demonstrated a confirmed ORR of 24% and an unconfirmed ORR of 29% among 68 efficacy-evaluable patients, with activity at 6mg/kg Q3W showing a confirmed ORR of 43% and an unconfirmed ORR of 48%[296] - BGB-58067 (PRMT5i) showed early responses at the second dose level in a Phase 1 study, with three objective responses observed in histologically distinct tumor types[331]

Business Highlights - BeiGene's Q1 2025 execution sets a strong foundation for the year, focusing on hematology franchise leadership, pipeline advancement, and superior financial performance[11] - Brukinsa is now the U S revenue leader among BTKis, with over 200,000 patients treated globally[17] - BeiGene has launched Brukinsa in Japan and it is now approved in 75 markets, with 11 new or expanded reimbursements including in Japan, EU, and Brazil[21] - Enrollment is complete in the Phase 3 CELESTIAL-TNCLL trial for Sonrotoclax, with global filing expected in R/R MCL in H2 2025[23] - BeiGene achieved GAAP profitability in Q1 2025, with GAAP Operating Income of $11 million compared to a loss of $261 million in Q1 2024[40] Financial Performance - Total revenue for Q1 2025 increased by 49% year-over-year, reaching $1.117 billion, compared to $752 million in Q1 2024[93, 95] - Net product revenue in Q1 2025 was $1.109 billion, a 48% increase from $747 million in Q1 2024[95, 96] - Brukinsa revenue in Q1 2025 reached $792 million, a 62% increase from $489 million in Q1 2024[95] - Tevimbra revenue in Q1 2025 was $171 million, an 18% increase from $145 million in Q1 2024[95] - GAAP earnings per ADS was $0.01 in Q1 2025, compared to a loss of $2.41 in Q1 2024[96]